Inogen, Inc. (INGN) incurred an adjusted loss per share of 45 cents for first-quarter 2024, which was narrower than the adjusted loss per share of 63 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 76 cents per share.GAAP loss per share for the quarter was 62 cents, narrower than the year-earlier loss of 88 cents per share.Revenues in DetailInogen registered revenues of $78 million for the first quarter, up 8.1% year over year. The figure surpassed the Zacks Consensus Esti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 33-0989359 (State or other jurisdiction of ( ...

Inogen, Inc. (NASDAQ:INGN) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and Chief Executive Officer Mike Bourque - Chief Financial Officer Conference Call Participants Colin Clark - Stifel Margaret Kaczor - William Blair Mike Matson - Needham & Company Operator Welcome to Inogen's First Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder ...

Inogen (INGN) reported $78.03 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.1%. EPS of -$0.62 for the same period compares to -$0.63 a year ago.The reported revenue represents a surprise of +6.48% over the Zacks Consensus Estimate of $73.28 million. With the consensus EPS estimate being -$0.76, the EPS surprise was +18.42%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Exhibit 99.1 Inogen Announces First Quarter 2024 Financial Results GOLETA, Calif., – May 07, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024. “We are pleased to be off to a solid start at Inogen in 2024. Looking forward, we remain focused on positioning the business for revenue growth, improving our operating discipline to drive long-term profitabi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer ...

Inogen, Inc. (NASDAQ:INGN) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants Marissa Bych - IR Gilmartin Group Kevin Smith - President and CEO Mike Sergesketter - Interim CFO Conference Call Participants Robbie Marcus – J.P. Morgan Margaret Kaczor Andrew - William Blair Mike Matson - Needham & Company Mathew Blackman - Stifel Operator Greetings, and welcome to the Inogen 2023 Fourth Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this confer ...

Ease of servicing saves distributors time and money Seeking regulatory approval to expand into U.S. market © 2024 Inogen, Inc. All Rights Reserved Sufficient capital to fund sustainable, organic growth Improving lives through respiratory care Rental ındgen Corporate Overview This presentation and the accompanying oral presentation (the "Presentation") include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estima ...

Fourth Quarter 2023 Financial Results Fourth quarter total revenue was $75.9 million, relative to $88.1 million in the fourth quarter of 2022, primarily due to a decrease in domestic business-to-business sales and direct-to-consumer sales, partially offset by higher rental revenue. Total gross margin was 37.1% in the fourth quarter of 2023 versus 33.5% in the comparative period in 2022. The increase was driven primarily by lower premiums paid for components and labor and overhead costs. Total operating expe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...